查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840888

抗精神病藥物市場（依藥物類別、給藥途徑、通路、劑型和適應症分類）－2025-2032 年全球預測

Antipsychotic Drugs Market by Drug Class, Route Of Administration, Distribution Channel, Formulation, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年抗精神病藥物市場規模將成長至 196.5 億美元，複合年成長率為 8.25%。

主要市場統計數據
基準年2024年 104.2億美元
預計2025年 112.8億美元
預測年份：2032年 196.5億美元
複合年成長率（%） 8.25%

全面、情境化的介紹，闡述了改變抗精神病治療途徑的臨床要求、交付模式和相關人員的優先事項

抗精神病治療領域正處於臨床需求、政策壓力和商業性轉型的交會點。近年來，分子藥理學的進步、製劑技術的改進以及治療模式的轉變，深刻地改變了臨床醫生和醫療保健系統對思覺失調症和雙相情感障礙的治療方式。患者對藥物耐受性和療效的要求日益提高，支付方要求藥物具有可證明的價值，製造商必須在生命週期管理和新產品開發之間取得平衡。

在此背景下，策略性相關人員需要簡潔的方向，重點在於突顯影響處方行為、處方投放和病患依從性的促進因素。為此，既要考慮第一代抗精神病藥物的傳統作用，也要考慮第二代抗精神病藥物不斷拓展的治療空間，同時也要認知到不斷變化的給藥途徑和分銷管道如何影響現實世界的藥物可及性。本介紹為這些動態提供了一個框架，並為更詳細的分析奠定了基礎，其核心主題是臨床結果、供應鏈連續性和付款人參與。

分析重新定義抗精神病治療模式和相關人員期望的臨床、技術和證據生成力量的融合。

在以患者為中心的醫療模式、藥理學創新和醫療體系現代化的推動下，抗精神病藥物領域正在發生重大變革。精準藥物選擇的意義不僅在於控制症狀，還在於降低代謝風險、改善認知功能和長期功能恢復。同時，製劑科學正在催生新的給藥方案，從而提高患者依從性並降低復發風險，從而改變住院和門診病人治療方案的計算方式。

同時，數位醫療工具和遠距精神病學正在擴大診斷範圍，並使得對治療反應和副作用的監測更加密切。這些技術正開始影響處方模式，促進臨床醫生和患者之間的共用決策，並使持續評估更加可行。此外，對真實世界證據的日益重視正在改變支付方用於制定承保決策的證據標準，醫療保健系統越來越重視長期療效和利用率指標，而非單一的臨床試驗終點。這些綜合變化迫使製造商比以往任何時候都更加緊密地協調臨床開發、商業策略和上市後證據的產生。

重點評估近期美國關稅變化如何改變抗精神病藥物商業化的供應鏈策略、採購選擇和競爭定位

關稅等政策措施可能會對整個醫藥價值鏈產生重大的下游影響，尤其是涉及原料藥、特殊輔助材料和成品進口時。對於依賴跨境採購原料藥和最終產品的製造商和經銷商而言，2025年將是一個不確定性加劇的時期。因此，籌資策略策略正轉向注重供應商多元化和庫存彈性，而商業團隊也正在重新評估各個分銷管道的服務成本假設。

這些與貿易相關的動態也會影響競爭格局。當關稅壓力導致進口產品的到岸成本上升時，擁有國內或周邊生產能力的製造商享有相對的商業性彈性。相反，依賴複雜國際供應鏈的公司可能會優先考慮合約對沖、供應商重新談判和營運投資，以降低風險。因此，貿易政策的不確定性可能會加速戰略舉措，例如本地化生產、加強原料藥供應的垂直整合以及與區域製造外包更緊密地合作。重要的是，雖然現有的安全性和有效性標準適用於臨床專案和監管提交，但產品發布和生命週期計畫的時間表可能會受到物流限制和成本控制決策的影響。

可操作的細分洞察，涵蓋藥物類別、給藥途徑、分銷管道、劑型和適應症，以最佳化臨床應用和商業性重點

穩健的細分能夠清楚展現臨床需求、應用模式和機會的交會點。依藥物類別分類，市場分為第一代抗精神病藥物（包括氯丙嗪、氟奮乃靜、Haloperidol、奮乃靜和硫利達嗪）和第二代抗精神病藥物（包括Aripiprazole、氯氮平、Olanzapine、QuetiapineRisperidone）。每類藥物的治療特性、耐受性和處方者偏好各不相同，進而影響其定位策略。

根據給藥途徑，產品分為注射劑和口服劑型，其中注射劑又分為肌肉注射和長效注射。分銷管道包括醫院、線上藥局和零售藥局，這些管道決定著病患的用藥模式、配藥實踐和付款人互動。劑型分類，例如口溶錠、液體製劑和片劑，會影響患者的接受度和診療機構的決策。最後，雙極性情感障礙和思覺失調症的適應症細分凸顯了臨床路徑、預期治療持續時間和療效指標的差異。這種細分有助於制定有針對性的上市方案、制定循證計劃，並根據臨床和商業性實際情況確定產品組合的優先順序。

區域戰略訊息，檢驗不同的醫療保健系統、報銷框架和獲取動態如何影響全球市場上抗精神病藥物的採用

區域促進因素持續以不同的方式影響臨床實踐、監管解讀和分銷物流。在美洲，醫療保健服務提供趨勢強調整合的行為健康服務、擴大社區護理，以及以結果和成本效益為優先的、由付款人主導的價值評估。這些因素影響處方集的配置決策，推動了對長效注射劑的投資，而這些注射劑的依從性挑戰會導致可避免的使用。

在歐洲、中東和非洲，監管協調工作與區域特定的報銷方法並存。根據各國國家衛生技術評估流程和資金籌措重點，該地區新藥和新配方的採用率各不相同。製造商必須客製化其證據包和定價策略，以滿足不同國家的需求。在亞太地區，快速的都市化、不斷擴大的保險覆蓋範圍以及日益增強的精神健康意識，正在推動對各種獲取途徑的需求，包括口服療法和數位化依從性工具。在所有地區，供應鏈的彈性、法規遵循以及符合文化背景的病人參與對於產品的成功發布和持續採用至關重要。此外，地緣政治和政策變化可能導致採購和分銷的地區差異，商業策略必須做出相應調整。

公司層面的競爭考察，重點在於產品組合深度、配方創新和策略夥伴關係，從而推動抗精神病藥物領域的競爭優勢

抗精神病藥物的競爭定位反映了傳統產品組合、創新劑型和差異化臨床證據的整合。現有企業透過平台藥物和廣泛的分銷網路保持顯著的市場地位，而專業的創新企業則專注於提高耐受性、依從性和長期功能療效。原廠藥與製造外包之間的夥伴關係在規模化生產方面仍然很常見，而與技術提供者的合作在依從性和監測解決方案方面也日益重要。

開發平臺既注重漸進式創新，例如改進給藥系統和配方，也注重針對具有更佳代謝特徵的症狀區域的新機制。商業性成功的團隊將生命週期管理與現實世界證據累積相結合，優先考慮早期付款人的參與，並保持靈活的供應策略以降低交易和採購波動。此外，在監管和衛生經濟學專業知識方面的人才投資正成為核心競爭力，使公司能夠應對複雜的報銷環境並展現相對價值。

為製造商和相關人員提供策略建議，以增強抗精神病藥物的彈性、證據生成和付款人友好的商業化

產業領導者應採取協調一致的策略，在短期營運韌性與長期臨床差異化之間取得平衡。首先，透過多元化原料藥和輔料的採購、盡可能擴大近岸生產以及建立透明的庫存和緊急時應對計畫來加強供應鏈。這將降低您受貿易相關中斷影響的風險，並支援所有管道的可預測產品供應。

其次，我們將投資於直接應對依從性和耐受性挑戰的配方和給藥創新，例如長效注射劑和口溶錠，同時將這些產品與數位化依從性監測解決方案相結合，以產生令人信服的真實世界證據。第三，我們將積極吸引付款人，開發基於結果的證據包，以反映長期效益並減少醫療保健利用率。第四，我們將採用靈活的商業模式，根據當地管道動態（包括醫院藥房、線上藥房和零售藥房）調整我們的銷售策略，並優先考慮促進藥物啟動和依從性的患者援助計畫。最後，我們將培養跨職能能力，例如衛生經濟學、監管策略和數據分析，以確保我們的臨床價值提案能夠轉化為報銷和持續採用。

一種透明的調查方法，結合臨床文獻綜合、專家訪談和供應鏈分析，以支持可辯護的策略結論

本研究綜合整合了多個來源的證據，為策略決策提供了透明且可重複的依據。調查方法結合了同行評審臨床研究的系統性文獻綜述、監管指南和藥品說明書變更分析，以及對臨床專家、付款方和商業領袖的結構化訪談，以捕捉真實世界的觀點。此外，供應鏈評估利用物流和採購數據來評估採購依賴和區域製造足跡。

將定性輸入與處方模式和醫療服務提供趨勢的二手資料進行交叉比對，以得出穩健的主題結論。在可能的情況下，研究結果透過專家諮詢小組檢驗，以確保其現實相關性並揭示預測風險。這種方法強調資料來源的可追溯性和分析假設的清晰度，使相關人員能夠在適當的臨床和商業性背景下解讀結論。隨著貿易和監管格局的演變，動態的政策和關稅環境需要定期重新評估。

明確的總結性總結強調了臨床差異化、證據生成和穩健的商業化策略的一致性，以實現長期影響

總而言之，抗精神病治療領域正處於曲折點，臨床預期、付款人督導和商業性執行必須緊密結合。製劑和給藥方式的創新解決了長期存在的依從性和耐受性挑戰，而數位健康和​​真實世界證據計劃則重新定義了價值的體現方式。同時，貿易政策的發展和日益複雜的供應鏈迫使製造商重新思考籌資策略，並增強其營運的韌性。

相關人員若能將產品開發、證據產生和上市工作協調一致，則最有可能獲得長期價值。這需要持續關注患者和付款人關注的成果，制定靈活的商業計劃以應對區域動態，並投資於將臨床差異化轉化為可衡量的醫療效益的能力。透過全面考慮臨床、監管和物流，組織可以從被動規劃轉向主動策略執行，從而支持患者照護和商業性永續性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 基於感測器技術的真實世界證據支持新型非典型抗精神病藥物的長期安全性
  • 思覺失調症
  • 受體偏向促效劑的出現，可最大限度地減少下一代抗精神病藥物的代謝副作用
  • 透過抗精神病治療中的藥物基因組學測試擴​​展個人化醫療
  • 開發長效注射劑以提高早期精神病患者的治療連續性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 抗精神病藥物市場（依藥物類別）

  • 第一代抗精神病藥物
    • 氯丙嗪
    • 氟奮乃靜
    • Haloperidol
    • 奮乃靜
    • 硫利達嗪
  • 第二代抗精神病藥物
    • Aripiprazole
    • 氯氮平
    • Olanzapine
    • Quetiapine
    • Risperidone

9. 抗精神病藥物市場（依給藥途徑）

  • 注射
    • 肌肉注射
    • 長效注射劑
  • 口服

第 10 章抗精神病藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章：抗精神病藥物市場（按處方）

  • 口溶錠
  • 解決方案
  • 藥片

第 12 章：抗精神病藥物市場（按適應症）

  • 躁鬱症
  • 思覺失調症

第 13 章：抗精神病藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章。抗精神病藥物市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各國抗精神病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Otsuka Holdings Co., Ltd.
    • Johnson & Johnson
    • AstraZeneca plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Novartis AG
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-AD36CD897CDF

The Antipsychotic Drugs Market is projected to grow by USD 19.65 billion at a CAGR of 8.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.42 billion
Estimated Year [2025] USD 11.28 billion
Forecast Year [2032] USD 19.65 billion
CAGR (%) 8.25%

A comprehensive contextual introduction that frames clinical imperatives, delivery models, and stakeholder priorities transforming antipsychotic therapy pathways

The therapeutic landscape for antipsychotic drugs sits at the intersection of clinical necessity, policy pressures, and commercial transformation. Over recent years, advances in molecular pharmacology, refinements in formulation technology, and shifts in care delivery models have together reshaped how clinicians and health systems approach treatment for schizophrenia and bipolar disorder. Patients increasingly demand tolerability alongside efficacy, payers insist on demonstrable value, and manufacturers must balance lifecycle management with novel product development.

Given this context, strategic stakeholders require a concise orientation that highlights the drivers influencing prescribing behavior, formulary placement, and patient adherence. To that end, it is critical to consider both the legacy role of first generation antipsychotics and the expanding therapeutic footprint of second generation agents, while also recognizing how routes of administration and evolving distribution channels influence real-world access. This introduction frames those dynamics and sets expectations for the deep-dive analyses that follow, emphasizing clinical outcomes, supply chain continuity, and payer engagement as core themes.

An analysis of converging clinical, technological, and evidence-generation forces that are redefining antipsychotic treatment paradigms and stakeholder expectations

The antipsychotic landscape is undergoing transformative shifts driven by patient-centric care models, pharmacological innovation, and broader health system modernization. Precision in agent selection has moved beyond symptomatic control to encompass metabolic risk mitigation, cognitive outcomes, and long-term functional recovery. Concurrently, formulation science has enabled new delivery options that improve adherence and reduce relapse risk, which in turn alters the calculus for hospital and outpatient care planning.

At the same time, digital health tools and telepsychiatry are expanding diagnostic reach and enabling closer monitoring of treatment response and adverse effects. These technologies are fostering shared decision-making between clinicians and patients and are beginning to influence prescribing patterns by making ongoing assessment more practical. Moreover, an emphasis on real-world evidence is changing the evidentiary bar for payer coverage decisions, with health systems increasingly focused on longitudinal outcomes and healthcare utilization metrics rather than isolated trial endpoints. These combined shifts are prompting manufacturers to align clinical development, commercial strategy, and post-market evidence generation more tightly than ever before.

A focused evaluation of how recent United States tariff changes are reshaping supply chain strategies, sourcing choices, and competitive positioning in antipsychotic drug commercialization

Policy instruments such as tariffs can have material downstream effects across the pharmaceutical value chain, particularly when applied to active pharmaceutical ingredients, specialized excipients, and finished dosage imports. In 2025, trade policy adjustments have introduced a period of elevated uncertainty for manufacturers and distributors that rely on cross-border sourcing of APIs and finished products. As a result, procurement strategies are shifting to emphasize supplier diversification and inventory resilience, while commercial teams reassess cost-to-serve assumptions across distribution channels.

These trade-related dynamics also influence the competitive environment. Where tariff pressures increase the landed cost of imported products, manufacturers with domestic or near-shore production capacity can gain relative commercial flexibility. Conversely, companies dependent on complex international supply chains may prioritize contractual hedging, renegotiation with suppliers, and operational investments to mitigate exposure. Trade policy uncertainty can therefore accelerate strategic moves such as localized manufacturing, increased vertical integration of API supply, and closer collaboration with contract manufacturing organizations that have regional footprints. Importantly, clinical programs and regulatory filings remain governed by existing safety and efficacy standards, but timelines for product launches and lifecycle initiatives may be affected by logistical constraints and cost management decisions.

Actionable segmentation insights that align drug class, administration route, distribution channel, formulation, and indication to optimize clinical adoption and commercial focus

Robust segmentation clarifies where clinical need, adoption patterns, and commercial opportunity intersect. By drug class, the market differentiates between first generation antipsychotics and second generation antipsychotics, with first generation agents including Chlorpromazine, Fluphenazine, Haloperidol, Perphenazine, and Thioridazine, while second generation agents include Aripiprazole, Clozapine, Olanzapine, Quetiapine, and Risperidone. Each class presents distinct therapeutic profiles, tolerability considerations, and prescriber preferences that affect positioning strategies.

By route of administration, products are categorized as Injectable and Oral, with Injectable formulations further distinguished by intramuscular and long-acting injectable options; the choice of route directly affects adherence, relapse prevention, and the operational requirements of care settings. Distribution channels encompass Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which shape patient access models, dispensing practices, and payer interactions. Formulation distinctions such as Orally Disintegrating Tablets, Solution, and Tablets influence patient acceptability and site-of-care decisions. Finally, indication segmentation across Bipolar Disorder and Schizophrenia underscores differences in clinical pathways, treatment duration expectations, and outcomes metrics. Together, these segmentation lenses enable targeted go-to-market approaches, evidence-generation plans, and portfolio prioritization that respond to both clinical and commercial realities.

Regional strategic intelligence examining how distinct healthcare systems, reimbursement frameworks, and access dynamics influence antipsychotic adoption across global markets

Regional dynamics continue to shape clinical practice, regulatory interpretation, and distribution logistics in distinct ways. In the Americas, healthcare delivery trends emphasize integrated behavioral health services, expanding community-based care, and payer-driven value assessments that prioritize outcomes and cost-effectiveness. These factors influence formulary placement decisions and encourage investment in long-acting injectables where adherence challenges drive avoidable utilization.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with localized reimbursement approaches; this region shows varied adoption speeds for newer agents and formulations based on national health technology assessment processes and funding priorities. Manufacturers must tailor evidence packages and pricing strategies to meet diverse national requirements. In Asia-Pacific, rapid urbanization, evolving insurance coverage, and expanding mental health awareness are creating increased demand for broad access options, including oral therapies and digital adherence tools. Across all regions, supply chain resilience, regulatory compliance, and culturally appropriate patient engagement are critical for successful product launches and sustained uptake. Moreover, geopolitical and policy shifts can introduce regional variability in procurement and distribution that commercial strategies must accommodate.

Insightful company-level analysis revealing how portfolio depth, formulation innovation, and strategic partnerships drive competitive advantage in antipsychotic therapeutics

Competitive positioning in antipsychotic therapeutics reflects a blend of legacy portfolios, novel formulations, and differentiated clinical evidence. Established companies maintain significant presence through foundational agents and broad distribution networks, while specialist innovators focus on improving tolerability, adherence, and long-term functional outcomes. Partnerships between originators and contract manufacturers remain common for scaling production, and alliances with technology providers are increasingly relevant for adherence and monitoring solutions.

R&D pipelines emphasize both incremental innovations-such as improved delivery systems and reformulations-and novel mechanisms targeting symptom domains with better metabolic profiles. Commercial teams that succeed are those which align lifecycle management with real-world evidence accumulation, prioritize payer engagement early, and maintain adaptive supply strategies to mitigate trade and sourcing volatility. Additionally, talent investment in regulatory affairs and health economics expertise is becoming a core competency, enabling firms to navigate complex reimbursement environments and demonstrate comparative value.

Actionable strategic recommendations for manufacturers and stakeholders to strengthen resilience, evidence generation, and payer-aligned commercialization in antipsychotic care

Industry leaders should pursue a coordinated strategy that balances near-term operational resilience with longer-term clinical differentiation. First, fortify supply chains by diversifying API and excipient sourcing, expanding near-shore manufacturing where feasible, and establishing transparent inventory and contingency planning. This will reduce exposure to trade-related disruptions and support predictable product availability across channels.

Second, invest in formulation and delivery innovations that directly address adherence and tolerability challenges, such as long-acting injectables and orally disintegrating tablets, while pairing these products with digital adherence and monitoring solutions to generate compelling real-world evidence. Third, engage payers proactively by developing outcomes-based evidence packages that reflect longitudinal benefits and reduced healthcare utilization. Fourth, adopt flexible commercial models that tailor distribution strategies to local channel dynamics-whether hospital pharmacy, online pharmacy, or retail pharmacy-and prioritize patient support programs that enhance initiation and persistence. Finally, cultivate cross-functional capabilities in health economics, regulatory strategy, and data analytics to ensure that clinical value propositions translate into reimbursement and sustainable uptake.

A transparent research methodology combining clinical literature synthesis, expert interviews, and supply chain analysis to support defensible strategic conclusions

This research synthesis integrates multi-source evidence to provide a transparent and reproducible foundation for strategic decisions. The methodology combines systematic literature review of peer-reviewed clinical studies, analysis of regulatory guidance and labeling changes, and structured interviews with clinical experts, payers, and commercial leaders to capture real-world perspectives. Additionally, supply chain assessments draw on logistics and procurement data to evaluate sourcing dependencies and regional manufacturing footprints.

Qualitative inputs were triangulated with secondary data on prescribing patterns and care-delivery trends to construct robust thematic conclusions. Wherever possible, findings were validated through expert advisory panels to ensure practical relevance and to surface anticipatory risks. The approach emphasizes traceability in data sourcing and clarity in analytical assumptions, enabling stakeholders to interpret conclusions within the appropriate clinical and commercial context. Limitations include the dynamic nature of policy and tariff environments, which necessitates periodic reassessment as trade and regulatory conditions evolve.

A decisive concluding synthesis emphasizing alignment of clinical differentiation, evidence generation, and resilient commercialization strategies for long-term impact

In conclusion, the antipsychotic therapeutics arena is at an inflection point where clinical expectations, payer scrutiny, and commercial execution must be tightly integrated. Innovations in formulation and delivery are addressing longstanding adherence and tolerability challenges, while digital health and real-world evidence initiatives are redefining how value is demonstrated. Concurrently, trade policy developments and supply chain complexities are encouraging manufacturers to reconsider sourcing strategies and to strengthen operational resilience.

Stakeholders who align product development, evidence generation, and market access efforts will be best positioned to capture long-term value. This requires a sustained focus on outcomes that matter to patients and payers, agile commercial planning responsive to regional dynamics, and investment in capabilities that translate clinical differentiation into measurable healthcare benefits. By synthesizing clinical, regulatory, and logistical considerations, organizations can move from reactive planning to proactive strategic execution that supports both patient care and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Real world evidence supporting long term safety profiles of novel atypical antipsychotics based on sensor technology
  • 5.2. Integration of digital therapeutics and mobile monitoring to enhance adherence in schizophrenia patients
  • 5.3. Emergence of receptor biased agonists minimizing metabolic side effects in next generation antipsychotics
  • 5.4. Expansion of personalized medicine through pharmacogenomic testing in antipsychotic therapy
  • 5.5. Development of long acting injectable formulations improving treatment continuity in early psychosis patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antipsychotic Drugs Market, by Drug Class

  • 8.1. First Generation Antipsychotics
    • 8.1.1. Chlorpromazine
    • 8.1.2. Fluphenazine
    • 8.1.3. Haloperidol
    • 8.1.4. Perphenazine
    • 8.1.5. Thioridazine
  • 8.2. Second Generation Antipsychotics
    • 8.2.1. Aripiprazole
    • 8.2.2. Clozapine
    • 8.2.3. Olanzapine
    • 8.2.4. Quetiapine
    • 8.2.5. Risperidone

9. Antipsychotic Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Long Acting Injectable
  • 9.2. Oral

10. Antipsychotic Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Antipsychotic Drugs Market, by Formulation

  • 11.1. Orally Disintegrating Tablets
  • 11.2. Solution
  • 11.3. Tablets

12. Antipsychotic Drugs Market, by Indication

  • 12.1. Bipolar Disorder
  • 12.2. Schizophrenia

13. Antipsychotic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antipsychotic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antipsychotic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Otsuka Holdings Co., Ltd.
    • 16.3.2. Johnson & Johnson
    • 16.3.3. AstraZeneca plc
    • 16.3.4. Eli Lilly and Company
    • 16.3.5. Pfizer Inc.
    • 16.3.6. Novartis AG
    • 16.3.7. H. Lundbeck A/S
    • 16.3.8. Teva Pharmaceutical Industries Ltd.
    • 16.3.9. Mylan N.V.
    • 16.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION